Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: A systematic review and economic evaluation

J Wilby; A Kainth; N Hawkins; D Epstein; H McIntosh; C McDaid; A Mason; S Golder; S O'Meara; M Sculpher; M Drummond; C Forbes

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: A systematic review and economic evaluation

J Wilby, A Kainth, N Hawkins, D Epstein, H McIntosh, C McDaid, A Mason, S Golder, S O'Meara, M Sculpher, M Drummond, C Forbes

Research output: Contribution to journal › Literature review › peer-review

Abstract

The aim of this review was to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults. For the purposes of this review newer antiepileptic drugs (AEDs) included gabapentin (GBP) (Neurontin(R), Parke-Davis), lamotrigine (LTG) (Lamictal(R), GlaxoSmithKline), levetiracetam (LEV) (Keppra(R), UCB Pharma), oxcarbazepine (OXC) (Trileptal(R), Novartis Pharmaceuticals), tiagabine (TGB) [Gabatril(R), Cephalon (UK)], topiramate (TPM) (Topomax(R), Janssen-Cilag) and vigabatrin (VGB) (Sabril(R), Hoechst Marion Roussel). A concurrent review was performed by the West Midlands Health Technology Assessment Collaboration (WMHTAC), Birmingham, to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in children.

Original language	English
Number of pages	158
Journal	Health technology assessment
Volume	9
Issue number	15
Publication status	Published - May 2005

Keywords

ADD-ON THERAPY
QUALITY-OF-LIFE
REFRACTORY PARTIAL EPILEPSY
NEWLY-DIAGNOSED EPILEPSY
COMPLEX PARTIAL SEIZURES
PLACEBO-CONTROLLED TRIAL
PARTIAL-ONSET SEIZURES
RESISTANT PARTIAL EPILEPSY
GAMMA-VINYL-GABA
VISUAL-FIELD DEFECTS

Access to Document

Mon915 1 finalFinal published version, 1.05 MB

http://www.hta.ac.uk/project/1304.asp

Cite this

Wilby, J., Kainth, A., Hawkins, N., Epstein, D., McIntosh, H., McDaid, C., Mason, A., Golder, S., O'Meara, S., Sculpher, M., Drummond, M., & Forbes, C. (2005). Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: A systematic review and economic evaluation. Health technology assessment, 9(15). http://www.hta.ac.uk/project/1304.asp

@article{9f7e9dc6f52f4a65ab43dd18a5467fb8,

title = "Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: A systematic review and economic evaluation",

abstract = "The aim of this review was to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults. For the purposes of this review newer antiepileptic drugs (AEDs) included gabapentin (GBP) (Neurontin(R), Parke-Davis), lamotrigine (LTG) (Lamictal(R), GlaxoSmithKline), levetiracetam (LEV) (Keppra(R), UCB Pharma), oxcarbazepine (OXC) (Trileptal(R), Novartis Pharmaceuticals), tiagabine (TGB) [Gabatril(R), Cephalon (UK)], topiramate (TPM) (Topomax(R), Janssen-Cilag) and vigabatrin (VGB) (Sabril(R), Hoechst Marion Roussel). A concurrent review was performed by the West Midlands Health Technology Assessment Collaboration (WMHTAC), Birmingham, to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in children.",

keywords = "ADD-ON THERAPY, QUALITY-OF-LIFE, REFRACTORY PARTIAL EPILEPSY, NEWLY-DIAGNOSED EPILEPSY, COMPLEX PARTIAL SEIZURES, PLACEBO-CONTROLLED TRIAL, PARTIAL-ONSET SEIZURES, RESISTANT PARTIAL EPILEPSY, GAMMA-VINYL-GABA, VISUAL-FIELD DEFECTS",

author = "J Wilby and A Kainth and N Hawkins and D Epstein and H McIntosh and C McDaid and A Mason and S Golder and S O'Meara and M Sculpher and M Drummond and C Forbes",

year = "2005",

month = may,

language = "English",

volume = "9",

journal = "Health technology assessment",

issn = "1366-5278",

publisher = "NHS National Institute for Health Research",

number = "15",

}

Wilby, J, Kainth, A, Hawkins, N, Epstein, D, McIntosh, H, McDaid, C , Mason, A , Golder, S , O'Meara, S , Sculpher, M , Drummond, M & Forbes, C 2005, 'Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: A systematic review and economic evaluation', Health technology assessment, vol. 9, no. 15. <http://www.hta.ac.uk/project/1304.asp>

TY - JOUR

T1 - Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: A systematic review and economic evaluation

AU - Wilby, J

AU - Kainth, A

AU - Hawkins, N

AU - Epstein, D

AU - McIntosh, H

AU - McDaid, C

AU - Mason, A

AU - Golder, S

AU - O'Meara, S

AU - Sculpher, M

AU - Drummond, M

AU - Forbes, C

PY - 2005/5

Y1 - 2005/5

N2 - The aim of this review was to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults. For the purposes of this review newer antiepileptic drugs (AEDs) included gabapentin (GBP) (Neurontin(R), Parke-Davis), lamotrigine (LTG) (Lamictal(R), GlaxoSmithKline), levetiracetam (LEV) (Keppra(R), UCB Pharma), oxcarbazepine (OXC) (Trileptal(R), Novartis Pharmaceuticals), tiagabine (TGB) [Gabatril(R), Cephalon (UK)], topiramate (TPM) (Topomax(R), Janssen-Cilag) and vigabatrin (VGB) (Sabril(R), Hoechst Marion Roussel). A concurrent review was performed by the West Midlands Health Technology Assessment Collaboration (WMHTAC), Birmingham, to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in children.

AB - The aim of this review was to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults. For the purposes of this review newer antiepileptic drugs (AEDs) included gabapentin (GBP) (Neurontin(R), Parke-Davis), lamotrigine (LTG) (Lamictal(R), GlaxoSmithKline), levetiracetam (LEV) (Keppra(R), UCB Pharma), oxcarbazepine (OXC) (Trileptal(R), Novartis Pharmaceuticals), tiagabine (TGB) [Gabatril(R), Cephalon (UK)], topiramate (TPM) (Topomax(R), Janssen-Cilag) and vigabatrin (VGB) (Sabril(R), Hoechst Marion Roussel). A concurrent review was performed by the West Midlands Health Technology Assessment Collaboration (WMHTAC), Birmingham, to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in children.

KW - ADD-ON THERAPY

KW - QUALITY-OF-LIFE

KW - REFRACTORY PARTIAL EPILEPSY

KW - NEWLY-DIAGNOSED EPILEPSY

KW - COMPLEX PARTIAL SEIZURES

KW - PLACEBO-CONTROLLED TRIAL

KW - PARTIAL-ONSET SEIZURES

KW - RESISTANT PARTIAL EPILEPSY

KW - GAMMA-VINYL-GABA

KW - VISUAL-FIELD DEFECTS

M3 - Literature review

SN - 1366-5278

VL - 9

JO - Health technology assessment

JF - Health technology assessment

IS - 15

ER -